Barnes PJ: New treatments for COPD. Nat Rev Drug Discov 2002, 1: 437–446.Barnes PJ (2002) New treatments for COPD. Nat Rev Drug Discov 1: 437–446Barnes PJ: New treatments for COPD . Nat Rev Drug Discov 2002, 1 :437–446.
New treatments for copd. Nat Rev Drug Discov 1, 437–446 (2002). https://doi.org/10.1038/nrd820 Download citation Issue Date01 June 2002 DOIhttps://doi.org/10.1038/nrd820 This article is cited by RETRACTED ARTICLE: Protein–Protein Interaction Network Analysis in Chronic Obstructive Pulmonary...
COPD is one of the most common diseases in the world, and there is a global increase in prevalence, but there are no drugs available at present that halt t... Barnes,Peter,J. - 《Nature Reviews Drug Discovery》 被引量: 156发表: 2002年 New treatments for COPD Chronic obstructive pulmonar...
These new treatments have also sparked interest in COPD cost-effectiveness research. Most COPD cost-effectiveness studies have been based on clinical trial populations, limited to direct medical costs, and used standard analysis methods such as Markov modelling, and they have usually found that newer...
Introduction: It has long been known that combining short-acting muscarinic antagonists and beta(2) agonists produces additive effects on the lung function of patients with chronic obstructive pulmonary disease (COPD). Two closely related approaches to provide long-acting treatments offering the same fu...
It encapsulates the research on nanoparticles within this domain, elucidating their applications in early screening, diagnostics, conventional treatments, targeted therapies, and immunotherapies for lung cancer. By critically assessing the strengths and limitations of various nanomaterials, along with their ...
This JAMA Insights explores the prevalence of episodic and chronic migraine in adults and acute and preventive treatments for migraine, such as novel calcitonin gene-related peptide receptor antagonists. Poetry and Medicine It Turns Out My Vertigo Was Caused by Meg Yardley, LCSW Abstract Full Text...
Q: Why is tailoring treatment for individual patients so important? DL:“Every COPD patient is unique and affected by the condition in different ways. Instead of a ‘one-size-fits-all’ approach, we need to tailor treatments and support to the specific needs of the individual. ...
While their primary function is to provide the necessary funds for medical treatments, wage replacements, and other benefits, it’s essential to remember that insurance companies are also businesses looking to minimize their financial liabilities. Here’s what you need to know about the role of ...
Data on demographics (age, gender, and weight), medical history (chronic renal disease, dialysis, immunodeficiency, transplantation, rheumatologic disease, diabetes, COPD, hemoglobinopathy, neurological disease, cancer, and cardiovascular disease), Charlson Comorbidity Index (CCI) [25], vaccination status...